CN118638091A - A method for synthesizing an oxabenzo[3.2.2]bridged ring compound skeleton - Google Patents
A method for synthesizing an oxabenzo[3.2.2]bridged ring compound skeleton Download PDFInfo
- Publication number
- CN118638091A CN118638091A CN202410927619.0A CN202410927619A CN118638091A CN 118638091 A CN118638091 A CN 118638091A CN 202410927619 A CN202410927619 A CN 202410927619A CN 118638091 A CN118638091 A CN 118638091A
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- solvent
- bridged ring
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical group 0.000 title abstract description 61
- 238000000034 method Methods 0.000 title abstract description 15
- 230000002194 synthesizing effect Effects 0.000 title abstract description 7
- 238000006243 chemical reaction Methods 0.000 abstract description 33
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 abstract description 12
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 abstract description 12
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 abstract description 11
- PRXNKYBFWAWBNZ-UHFFFAOYSA-N trimethylphenylammonium tribromide Chemical compound Br[Br-]Br.C[N+](C)(C)C1=CC=CC=C1 PRXNKYBFWAWBNZ-UHFFFAOYSA-N 0.000 abstract description 9
- BADXJIPKFRBFOT-UHFFFAOYSA-N dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 abstract description 8
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 abstract description 8
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 7
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 abstract description 7
- 239000003513 alkali Substances 0.000 abstract description 6
- 238000006845 Michael addition reaction Methods 0.000 abstract description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract description 5
- 238000007171 acid catalysis Methods 0.000 abstract description 4
- 238000006555 catalytic reaction Methods 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 3
- 230000001335 demethylating effect Effects 0.000 abstract description 3
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000010189 synthetic method Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 23
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 239000002904 solvent Substances 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohex-2-enone Chemical compound O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 description 14
- 239000007787 solid Substances 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- 239000003208 petroleum Substances 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 229910052786 argon Inorganic materials 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000001308 synthesis method Methods 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 150000001879 copper Chemical class 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229910015900 BF3 Inorganic materials 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 101001121408 Homo sapiens L-amino-acid oxidase Proteins 0.000 description 2
- 102100026388 L-amino-acid oxidase Human genes 0.000 description 2
- 101100012902 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FIG2 gene Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 235000009120 camo Nutrition 0.000 description 2
- 235000005607 chanvre indien Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000011487 hemp Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229910000928 Yellow copper Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明提供了一种氧杂苯并[3.2.2]桥环化合物骨架的合成方法,该方法包括:将5,5‑二甲基‑1,3‑环己二酮在酸催化重排得到化合物I,经过碱水解得到化合物II,经硫酸二甲酯对酚羟基进行保护得到化合物III,在氰化亚铜催化与2‑环己烯‑1‑酮进行迈克尔加成得到化合物IV,经乙硫醇钠选择性脱甲基得到化合物V,经苯基三甲基三溴化铵溴化后再经碱进行分子内SN2反应得到化合物VI,即为氧杂苯并[3.2.2]桥环化合物骨架。该合成方法克服了现有技术试剂昂贵、收率低等缺陷,便于后续含氧杂苯并[3.2.2]桥环化合物骨架的相关化合物的大量生产,具备较好的应用前景。
The invention provides a method for synthesizing an oxobenzo[3.2.2] bridged ring compound skeleton, the method comprising: rearranging 5,5-dimethyl-1,3-cyclohexanedione in acid catalysis to obtain compound I, hydrolyzing with alkali to obtain compound II, protecting phenolic hydroxyl group with dimethyl sulfate to obtain compound III, performing Michael addition with 2-cyclohexene-1-ketone in cuprous cyanide catalysis to obtain compound IV, selectively demethylating with sodium ethanethiolate to obtain compound V, brominating with phenyltrimethylammonium tribromide and then performing intramolecular S N 2 reaction with alkali to obtain compound VI, i.e., an oxobenzo[3.2.2] bridged ring compound skeleton. The synthetic method overcomes the defects of expensive reagents and low yield in the prior art, is convenient for the mass production of related compounds of subsequent oxobenzo[3.2.2] bridged ring compound skeletons, and has good application prospects.
Description
技术领域Technical Field
本发明属于有机合成技术领域,具体的涉及一种氧杂苯并[3.2.2]桥环化合物骨架的合成方法。The invention belongs to the technical field of organic synthesis, and specifically relates to a method for synthesizing an oxabenzo[3.2.2]bridged ring compound skeleton.
背景技术Background Art
氧杂苯并[3.2.2]桥环结构是近年来被科学家研究和关注较多的一类天然产物中的结构。含有该结构的化合物广泛分布在植物界,并且具有多样且显著的生物活性。含有该骨架的天然产物Cannabispirketa是从汉麻叶中分离得到,汉麻具有麻醉、止咳止喘、解痉止痛、止血散淤、解毒安胎等功效;同时,Cannabispirketa具抑制乳腺癌细胞(MCF-7)增殖和诱导凋亡等良好生物活性。由此可见,[3.2.2]桥环分子化合物的合成与开发在药物研究和生物学中具有很大的潜力,对后期科研人员研究如何合成相关产物提供了的新方向。The oxabenzo[3.2.2] bridge ring structure is a type of natural product that has been studied and paid more attention by scientists in recent years. Compounds containing this structure are widely distributed in the plant kingdom and have diverse and significant biological activities. Cannabispirketa, a natural product containing this skeleton, is isolated from hemp leaves. Hemp has the effects of anesthesia, antitussive and antiasthmatic, antispasmodic and analgesic, hemostatic and blood stasis, detoxification and fetal protection; at the same time, Cannabispirketa has good biological activities such as inhibiting the proliferation of breast cancer cells (MCF-7) and inducing apoptosis. It can be seen that the synthesis and development of [3.2.2] bridge ring molecular compounds have great potential in drug research and biology, and provide a new direction for later researchers to study how to synthesize related products.
我们相信,还有更多的未知活性与药用价值等着人类的不断探索与发现。目前,有少许课题组完成了[3.2.2]桥环化合物的构筑及含有该骨架的天然产物的全合成,但合成氧杂苯并[3.2.2]桥环化合物的研究还未见报道。We believe that there are more unknown activities and medicinal values waiting for human exploration and discovery. At present, a few research groups have completed the construction of [3.2.2] bridged ring compounds and the total synthesis of natural products containing this skeleton, but the research on the synthesis of oxybenzo[3.2.2] bridged ring compounds has not been reported.
发明内容Summary of the invention
本发明主要是克服现有技术中的不足之处,提出一种氧杂苯并[3.2.2]桥环化合物骨架的合成方法,该方法包括:将5,5-二甲基-1,3-环己二酮在酸催化重排得到化合物I,经过碱水解得到化合物II,经硫酸二甲酯对酚羟基进行保护得到化合物III,在氰化亚铜催化与2-环己烯-1-酮进行迈克尔加成得到化合物IV,经乙硫醇钠选择性脱甲基得到化合物V,经苯基三甲基三溴化铵溴化后再经碱进行分子内SN2反应得到化合物VI,即为氧杂苯并[3.2.2]桥环化合物骨架。该合成方法克服了现有技术试剂昂贵、收率低等缺陷,便于后续含氧杂苯并[3.2.2]桥环化合物骨架的相关化合物的大量生产,具备较好的应用前景。The present invention mainly overcomes the shortcomings of the prior art and proposes a method for synthesizing an oxybenzo[3.2.2] bridged ring compound skeleton, which comprises: rearranging 5,5-dimethyl-1,3-cyclohexanedione under acid catalysis to obtain compound I, hydrolyzing it with alkali to obtain compound II, protecting the phenolic hydroxyl group with dimethyl sulfate to obtain compound III, performing Michael addition with 2-cyclohexene-1-one under cuprous cyanide catalysis to obtain compound IV, selectively demethylating it with sodium ethanethiolate to obtain compound V, brominating it with phenyltrimethylammonium tribromide and then performing intramolecular S N 2 reaction with alkali to obtain compound VI, which is an oxybenzo[3.2.2] bridged ring compound skeleton. The synthesis method overcomes the defects of the prior art such as expensive reagents and low yield, facilitates the subsequent mass production of related compounds containing the oxybenzo[3.2.2] bridged ring compound skeleton, and has good application prospects.
为了实现上述技术目的,本发明采用的技术方案为:In order to achieve the above technical objectives, the technical solution adopted by the present invention is:
一种氧杂苯并[3.2.2]桥环化合物骨架的合成方法,合成路线如下所示:A method for synthesizing an oxabenzo[3.2.2]bridged ring compound skeleton, the synthesis route is as follows:
。 .
所述合成方法包括步骤1至步骤6:The synthesis method comprises steps 1 to 6:
具体的:Specific:
步骤1:化合物5,5-二甲基-1,3-环己二酮作为起始原料,高温回流条件下经酸催化重排得到化合物I;Step 1: Compound 5,5-dimethyl-1,3-cyclohexanedione is used as a starting material and rearranged under high temperature reflux conditions by acid catalysis to obtain compound I;
步骤2:化合物I用氢氧化钠水溶液加热水解得到化合物II;Step 2: Compound I is heated and hydrolyzed with sodium hydroxide aqueous solution to obtain compound II;
步骤3:化合物II用硫酸二甲酯对酚羟基进行保护得到III;Step 3: The phenolic hydroxyl group of compound II is protected with dimethyl sulfate to obtain III;
步骤4:化合物III在氰化亚铜的催化下与2-环己烯-1-酮进行迈克尔加成得到化合物IV;Step 4: Compound III is subjected to Michael addition reaction with 2-cyclohexene-1-one under the catalysis of cuprous cyanide to obtain compound IV;
步骤5:化合物IV用乙硫醇钠选择性脱掉与甲基邻位的酚甲基醚上的甲基得到化合物V;Step 5: Compound IV is treated with sodium ethanethiolate to selectively remove the methyl group of the phenol methyl ether adjacent to the methyl group to obtain compound V;
步骤6:化合物V用苯基三甲基三溴化铵进行溴化反应,后用氢氧化钠水溶液对溴代后的底物进行分子内SN2反应得到化合物VI,即为氧杂苯并[3.2.2]桥环化合物骨架;Step 6: Compound V is subjected to bromination reaction with phenyltrimethylammonium tribromide, and then the brominated substrate is subjected to intramolecular SN2 reaction with sodium hydroxide aqueous solution to obtain compound VI, which is an oxabenzo[3.2.2] bridged ring compound skeleton;
所述化合物VI为氧杂苯并[3.2.2]桥环化合物骨架,结构式如下:The compound VI is an oxabenzo[3.2.2] bridged ring compound skeleton, and the structural formula is as follows:
。 .
进一步的,所述化合物5,5-二甲基-1,3-环己二酮与化合物I-IX的结构式分别如下所示:Furthermore, the structural formulas of the compound 5,5-dimethyl-1,3-cyclohexanedione and compound I-IX are respectively as follows:
。 .
进一步的,所述步骤1的具体合成方法为:Furthermore, the specific synthesis method of step 1 is:
室温下搭建无水无氧的回流装置,装置中加入5,5-二甲基-1,3-环己二酮,加入溶剂乙酸酐,缓慢加入浓硫酸,后加热至139℃ - 150℃回流1-3小时,除去乙酸酐,依次经过冰水稀释,萃取,再依次用饱和碳酸氢钠溶液、蒸馏水和饱和食盐水洗涤,最后干燥,除去溶剂后,分离纯化得到化合物I;A water-free and oxygen-free reflux device is built at room temperature, 5,5-dimethyl-1,3-cyclohexanedione is added to the device, acetic anhydride is added as a solvent, concentrated sulfuric acid is slowly added, and then the mixture is heated to 139° C. - 150° C. and refluxed for 1-3 hours to remove acetic anhydride, followed by dilution with ice water, extraction, and washing with saturated sodium bicarbonate solution, distilled water, and saturated brine, and finally drying, removing the solvent, and separating and purifying to obtain compound I;
所述5,5-二甲基-1,3-环己二酮和浓硫酸的摩尔比为71.30-74.30:78.50-81.30。The molar ratio of the 5,5-dimethyl-1,3-cyclohexanedione to the concentrated sulfuric acid is 71.30-74.30:78.50-81.30.
进一步的,所述步骤2的具体合成方法为:Furthermore, the specific synthesis method of step 2 is:
化合物I经过氢氧化钠水溶液水解得到化合物II,具体包括:Compound I is hydrolyzed with sodium hydroxide aqueous solution to obtain compound II, which specifically comprises:
常温下在装置中加入化合物I,再加入溶剂乙醇,后在冰浴下成滴状加入氢氧化钠水溶液,再升温至58°C-65 °C常压反应1-3小时;反应结束后,调pH值,除去乙醇,再依次用饱和碳酸氢钠溶液、水和饱和食盐水洗涤,最后干燥,除去溶剂后,分离纯化即可得到化合物II;Add compound I to the device at room temperature, then add solvent ethanol, then add sodium hydroxide aqueous solution in drops under an ice bath, then heat to 58°C-65°C and react at normal pressure for 1-3 hours; after the reaction, adjust the pH value, remove ethanol, then wash with saturated sodium bicarbonate solution, water and saturated brine in sequence, finally dry, remove the solvent, and separate and purify to obtain compound II;
所述化合物I和氢氧化钠摩尔比为60.30-63.30:17.18-20.18。The molar ratio of the compound I to sodium hydroxide is 60.30-63.30:17.18-20.18.
进一步的,所述步骤3的具体合成方法为:Furthermore, the specific synthesis method of step 3 is:
化合物II对其进行硫酸二甲酯对酚羟基进行甲基化得到化合物III,具体包括:Compound II is subjected to dimethyl sulfate to methylate the phenolic hydroxyl group to obtain compound III, which specifically comprises:
常温下在反应装置里加入化合物Ⅱ和无水碳酸钾,再加入溶剂丙酮;再缓慢滴加硫酸二甲酯,升温至58°C-65°C回流10-14小时,反应结束滤去碳酸钾固体,依次用饱和碳酸氢钠溶液、水和饱和食盐水洗涤,最后干燥,除去溶剂后,分离纯化即可得到化合物III;Add compound II and anhydrous potassium carbonate into the reaction device at room temperature, and then add solvent acetone; then slowly add dimethyl sulfate dropwise, raise the temperature to 58°C-65°C and reflux for 10-14 hours. After the reaction is completed, filter out the potassium carbonate solid, wash with saturated sodium bicarbonate solution, water and saturated brine in sequence, and finally dry. After removing the solvent, separate and purify to obtain compound III;
所述化合物Ⅱ、无水碳酸钾及硫酸二甲酯的摩尔比为44.88-47.88:128.19-131.19:134.62-137.62。The molar ratio of the compound II, anhydrous potassium carbonate and dimethyl sulfate is 44.88-47.88:128.19-131.19:134.62-137.62.
进一步的,所述步骤4的具体合成方法为:Furthermore, the specific synthesis method of step 4 is:
化合物III通过与2-环己烯-1-酮进行迈克尔加成得到化合物IV,具体包括:Compound III is subjected to Michael addition reaction with 2-cyclohexene-1-one to obtain compound IV, which specifically comprises:
0℃--5℃下,在反应装置中加入化合物III和溶剂四氢呋喃,随后缓慢滴加正丁基锂至反应瓶中,反应10-20分钟后恢复至室温反应2.5-4小时,得到锂试剂;At 0°C-5°C, add compound III and solvent tetrahydrofuran into the reaction device, then slowly drop n-butyl lithium into the reaction bottle, react for 10-20 minutes, then return to room temperature and react for 2.5-4 hours to obtain a lithium reagent;
常温下加入氰化亚铜和溶剂四氢呋喃,在-78℃--80℃下缓慢滴加在所述锂试剂中,随后转移至0℃--5℃下搅拌10-20分钟,再转入-78℃--80℃反应1-3小时,结束后得到铜盐溶液;Add cuprous cyanide and solvent tetrahydrofuran at room temperature, slowly dropwise add them into the lithium reagent at -78°C--80°C, then transfer to 0°C--5°C and stir for 10-20 minutes, then transfer to -78°C--80°C and react for 1-3 hours, and after completion, obtain a copper salt solution;
将2-环己烯-1-酮,三氟化硼乙醚溶液和超干四氢呋喃在反应瓶内混匀,在-78℃下缓慢滴加入进入铜盐溶液中,于-78℃--80℃下反应4-6小时;加入饱和氯化铵水溶液淬灭,依次用饱和碳酸氢钠溶液、水和饱和食盐水洗涤,最后干燥,除去溶剂后,分离纯化即可得到化合物IV;2-cyclohexen-1-one, boron trifluoride ether solution and ultra-dry tetrahydrofuran are mixed in a reaction bottle, slowly added dropwise into the copper salt solution at -78°C, and reacted at -78°C-80°C for 4-6 hours; saturated ammonium chloride aqueous solution is added to quench, and the mixture is washed with saturated sodium bicarbonate solution, water and saturated brine in sequence, and finally dried, and after removing the solvent, the mixture is separated and purified to obtain compound IV;
所述化合物III,正丁基锂,氰化亚铜,2-环己烯-1-酮及三氟化硼乙醚的摩尔比为78.51-81.51:82.44-85.44:58.88-61.88:39.26-42.26:39.26-43.26。The molar ratio of the compound III, n-butyl lithium, cuprous cyanide, 2-cyclohexene-1-one and boron trifluoride etherate is 78.51-81.51: 82.44-85.44: 58.88-61.88: 39.26-42.26: 39.26-43.26.
进一步的,所述步骤5的具体合成方法为:Furthermore, the specific synthesis method of step 5 is:
化合物IV经乙硫醇钠选择性脱甲基得到化合物V,具体包括:Compound IV is selectively demethylated by sodium ethanethiolate to obtain compound V, specifically comprising:
室温下在反应装置中加入化合物IV和N,N-二甲基甲酰胺,随后在搅拌下加入乙硫醇钠固体,升温至153℃-160℃反应6-10小时,常压;反应结束后,加入稀盐酸水溶液淬灭,依次用饱和碳酸氢钠溶液、水和饱和食盐水洗涤,最后干燥,除去溶剂后,分离纯化即可得到化合物V;Add compound IV and N,N-dimethylformamide to a reaction device at room temperature, then add sodium ethanethiolate solid under stirring, heat to 153°C-160°C and react for 6-10 hours at normal pressure; after the reaction, add dilute hydrochloric acid aqueous solution to quench, wash with saturated sodium bicarbonate solution, water and saturated brine in sequence, and finally dry, remove the solvent, separate and purify to obtain compound V;
所述化合物IV和乙硫醇钠的摩尔比为:4.27-7.27:13.67-16.67。The molar ratio of the compound IV to sodium ethanethiolate is: 4.27-7.27:13.67-16.67.
进一步的,所述步骤6的具体合成方法为:Furthermore, the specific synthesis method of step 6 is:
化合物V用苯基三甲基三溴化铵溴化,后用氢氧化钠水溶液进行分子内SN2反应得到VI,具体包括:Compound V is brominated with phenyltrimethylammonium tribromide, and then subjected to an intramolecular SN2 reaction with an aqueous sodium hydroxide solution to obtain VI, specifically comprising:
室温下在反应装置中加入苯基三甲基三溴化铵和四氢呋喃,将其配置成溶液;在室温下将化合物V用四氢呋喃溶解置于-78℃的低温浴中,再缓慢逐滴将苯基三甲基三溴化铵的四氢呋喃溶液加入其中,-78℃--80℃下反应3-5小时后,移至室温反应12-16小时,反应结束后抽滤固体,除去溶剂得黄色固体备用;Add phenyltrimethylammonium tribromide and tetrahydrofuran to a reaction device at room temperature to prepare a solution; dissolve compound V in tetrahydrofuran at room temperature and place in a low-temperature bath at -78°C, then slowly add the tetrahydrofuran solution of phenyltrimethylammonium tribromide dropwise thereto, react at -78°C-80°C for 3-5 hours, then move to room temperature to react for 12-16 hours, and after the reaction is completed, filter the solid by suction, remove the solvent, and obtain a yellow solid for standby use;
将所得的黄色固体用溶剂二氯甲烷溶解并转移至反应装置中,0℃下缓慢加入稀氢氧化钠溶液,转移至室温反应30-50分钟,反应结束依次用饱和碳酸氢钠溶液、水和饱和食盐水洗涤,最后干燥,除去溶剂后,分离纯化得化合物Ⅵ;The obtained yellow solid was dissolved with a solvent of dichloromethane and transferred to a reaction device, and a dilute sodium hydroxide solution was slowly added at 0°C, and the mixture was transferred to room temperature for reaction for 30-50 minutes. After the reaction, the mixture was washed with a saturated sodium bicarbonate solution, water and saturated brine in sequence, and finally dried. After removing the solvent, the compound VI was separated and purified;
所述化合物Ⅴ,苯基三甲基三溴化铵及NaOH的摩尔比为2.02-5.02:6.25-9.25:0.02-0.05。The molar ratio of the compound V, phenyltrimethylammonium tribromide and NaOH is 2.02-5.02:6.25-9.25:0.02-0.05.
有益效果Beneficial Effects
与现有技术相比,本发明具有以下优点:Compared with the prior art, the present invention has the following advantages:
本发明提出一种氧杂苯并[3.2.2]桥环化合物骨架的合成方法,该方法包括:将5,5-二甲基-1,3-环己二酮在酸催化重排得到化合物I,经过碱水解得到化合物II,经硫酸二甲酯对酚羟基进行保护得到化合物III,在氰化亚铜催化与2-环己烯-1-酮进行迈克尔加成得到化合物IV,经乙硫醇钠选择性脱甲基得到化合物V,经苯基三甲基三溴化铵溴化后再经碱进行分子内SN2反应得到化合物VI,即为氧杂苯并[3.2.2]桥环化合物骨架。该合成方法克服了现有技术试剂昂贵、收率低等缺陷,便于后续含氧杂苯并[3.2.2]桥环化合物骨架的相关化合物的大量生产,具备较好的应用前景。The present invention provides a method for synthesizing an oxybenzo[3.2.2] bridged ring compound skeleton, which comprises: rearranging 5,5-dimethyl-1,3-cyclohexanedione under acid catalysis to obtain compound I, hydrolyzing it with alkali to obtain compound II, protecting phenolic hydroxyl group with dimethyl sulfate to obtain compound III, performing Michael addition with 2-cyclohexene-1-one under cuprous cyanide catalysis to obtain compound IV, selectively demethylating with sodium ethanethiolate to obtain compound V, brominating with phenyltrimethylammonium tribromide and then performing intramolecular S N 2 reaction with alkali to obtain compound VI, which is an oxybenzo[3.2.2] bridged ring compound skeleton. The synthesis method overcomes the defects of expensive reagents and low yield in the prior art, facilitates the subsequent mass production of related compounds containing the oxybenzo[3.2.2] bridged ring compound skeleton, and has good application prospects.
附图说明BRIEF DESCRIPTION OF THE DRAWINGS
图1为本发明实施例中氧杂苯并[3.2.2]桥环化合物的合成路径图;FIG1 is a synthetic route diagram of the oxabenzo[3.2.2]bridged ring compound in an embodiment of the present invention;
图2为实施例中化合物I~Ⅵ的结构式。FIG2 is the structural formula of compounds I to VI in the examples.
具体实施方式DETAILED DESCRIPTION
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
按照图1所示的合成路径图,合成下列实施例中的化合物,涉及到的各个化合物的结构式图2所示。According to the synthesis route shown in FIG1 , the compounds in the following examples were synthesized, and the structural formulas of the compounds involved are shown in FIG2 .
实施例1:Embodiment 1:
步骤1:Step 1:
取双口圆底烧瓶并搭建无水无氧的回流装置,称取5,5-二甲基-1,3环己二酮(10g,71.30mmol,1.0equiv)加入双口瓶中再次置换氩气三次。在室温下,加入乙酸酐(111mL)稀释底物后,缓慢滴加硫酸(4.20mL,78.50mmol,1.1equiv),升温至139℃回流1小时,反应结束后,待体系冷却,减压浓缩除去乙酸酐,加入冰水稀释(200mL)并搅拌20min,二氯甲烷萃取(50mL×3);再依次用饱和碳酸氢钠溶液(50mL)、蒸馏水(50mL)和饱和食盐水洗涤(50mL),最后加入适量无水硫酸钠干燥,减压浓缩除去溶剂后,利用柱层析进行分离纯化,洗脱剂体积比为(石油醚:乙酸乙酯=12:1),得到棕黄色油状化合物I(13.40g,84%)。Rf=0.5(石油醚:乙酸乙酯=4:1)。Take a two-necked round-bottom flask and set up an anhydrous and oxygen-free reflux device, weigh 5,5-dimethyl-1,3-cyclohexanedione (10 g, 71.30 mmol, 1.0 equiv), add it into the two-necked flask, and replace the argon gas three times again. At room temperature, acetic anhydride (111 mL) was added to dilute the substrate, sulfuric acid (4.20 mL, 78.50 mmol, 1.1 equiv) was slowly added dropwise, the temperature was raised to 139 ° C and refluxed for 1 hour. After the reaction was completed, the system was cooled, concentrated under reduced pressure to remove acetic anhydride, ice water (200 mL) was added to dilute and stirred for 20 min, and extracted with dichloromethane (50 mL×3); then washed with saturated sodium bicarbonate solution (50 mL), distilled water (50 mL) and saturated brine (50 mL) in turn, and finally dried with an appropriate amount of anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and separated and purified by column chromatography, the eluent volume ratio was (petroleum ether: ethyl acetate = 12: 1), and brown oily compound I (13.40 g, 84%) was obtained. R f = 0.5 (petroleum ether: ethyl acetate = 4: 1).
步骤2:Step 2:
取250 mL双口圆底烧瓶,干燥并置换氩气三次,将化合物I (13.40 g, 60.30mmol, 1.0 equiv) 溶于无水乙醇 (100 mL) 并转移至反应瓶中,在室温下缓慢逐滴滴加氢氧化钠 (6.87 g, 17.18 mmol 2.85 equiv) 的水溶液 (11 -mL),升温至60 ℃ 反应1小时,反应结束后,待体系冷却,用4 N 盐酸溶液调pH至中性后,减压浓缩除去乙醇后抽滤,所得滤液再依次用饱和碳酸氢钠溶液 (50 mL)、水 (30 mL) 和饱和食盐水洗涤 (30 mL),最后加入适量无水硫酸钠干燥,减压浓缩除去溶剂后,利用柱层析进行分离纯化,洗脱剂体积比为 (石油醚:乙酸乙酯 = 4 : 1),得到淡黄色固体化合物Ⅱ (6.20 g, 74%)。Rf= 0.4(石油醚:乙酸乙酯 = 2 : 1)。Take a 250 mL double-necked round-bottom flask, dry it and replace argon three times, dissolve compound I (13.40 g, 60.30mmol, 1.0 equiv) in anhydrous ethanol (100 mL) and transfer it to a reaction bottle, slowly add sodium hydroxide (6.87 g, 17.18 mmol 2.85 equiv) in water (11-mL) dropwise at room temperature, heat to 60 ° C and react for 1 hour. After the reaction, wait for the system to cool, adjust the pH to neutral with 4 N hydrochloric acid solution, concentrate under reduced pressure to remove ethanol and filter, and the filtrate is washed with saturated sodium bicarbonate solution (50 mL), water (30 mL) and saturated brine (30 mL) in turn, and finally add an appropriate amount of anhydrous sodium sulfate to dry, concentrate under reduced pressure to remove the solvent, and separate and purify it by column chromatography. The eluent volume ratio is (petroleum ether: ethyl acetate = 4: 1) to obtain a light yellow solid compound II (6.20 g, 74%). R f = 0.4 (petroleum ether:ethyl acetate = 2:1).
步骤3:Step 3:
取250 mL双口圆底烧瓶并搭建无水无氧的回流装置,干燥并置换氩气三次后依次称取化合物II (6.20 g, 44.88 mmol, 1.0 equiv)和无水碳酸钾 (15.51 g, 128.19mmol, 2.5 equiv),后再次置换氩气三次。室温下加入丙酮 (80 mL)稀释底物 ,后逐滴滴加硫酸二甲酯 (12.74 mL, 134.62 mmol 3.0 equiv),升温至58 ℃回流10小时。反应结束待体系冷却至室温,滤去碳酸钾固体,并用乙酸乙酯冲洗滤饼。收集的滤液依次用饱和碳酸氢钠溶液 (50 mL)、水 (30 mL) 和饱和食盐水(30 mL) 洗涤,最后加入适量无水硫酸钠干燥,减压浓缩除去溶剂后,利用柱层析进行分离纯化,洗脱剂体积比为 (石油醚:乙酸乙酯= 25 : 1),得到乳白色油状化合物III (5.84 g, 78%)。Rf= 0.7 (石油醚:乙酸乙酯 = 4: 1)。Take a 250 mL double-necked round-bottom flask and set up an anhydrous and oxygen-free reflux device. After drying and replacing argon three times, weigh compound II (6.20 g, 44.88 mmol, 1.0 equiv) and anhydrous potassium carbonate (15.51 g, 128.19mmol, 2.5 equiv) in turn, and then replace argon three times again. Add acetone (80 mL) at room temperature to dilute the substrate, then add dimethyl sulfate (12.74 mL, 134.62 mmol 3.0 equiv) dropwise, heat to 58 °C and reflux for 10 hours. After the reaction is completed, wait for the system to cool to room temperature, filter out the potassium carbonate solid, and rinse the filter cake with ethyl acetate. The collected filtrate was washed with saturated sodium bicarbonate solution (50 mL), water (30 mL) and saturated brine (30 mL) in turn, and finally dried with an appropriate amount of anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and separated and purified by column chromatography, with the eluent volume ratio of (petroleum ether: ethyl acetate = 25: 1), to obtain a milky white oily compound III (5.84 g, 78%). R f = 0.7 (petroleum ether: ethyl acetate = 4: 1).
步骤4:Step 4:
取250 mL单口圆底烧瓶干燥,置换氩气三次后,在常温下取60 mL超干四氢呋喃将化合物III (13.05 g, 78.51 mmol, 2.0 equiv)溶解并转移至单口瓶中。于0 ℃下缓慢滴加正丁基锂 (32.99 mL, 82.44 mmol, 2.1 equiv, 2.5 M 己烷溶液)至反应瓶中。滴加完毕后,该温度下继续反应10分钟,后升温至室温反应2.5小时,得到锂试剂备用。Take a 250 mL single-mouth round-bottom flask and dry it. After replacing the argon three times, take 60 mL of ultra-dry tetrahydrofuran at room temperature to dissolve compound III (13.05 g, 78.51 mmol, 2.0 equiv) and transfer it to a single-mouth flask. Slowly add n-butyl lithium (32.99 mL, 82.44 mmol, 2.1 equiv, 2.5 M hexane solution) to the reaction flask at 0 °C. After the addition is complete, continue to react at this temperature for 10 minutes, then heat to room temperature for 2.5 hours to obtain the lithium reagent for use.
取250mL双口圆底烧瓶干燥,置换氩气三次,称取氰化亚铜(5.33g,58.88mmol,1.5equiv)添加至双口瓶中,再次置换三次氩气,取15mL重蒸后的四氢呋喃加入双口瓶中,在-78℃下,抽取上一步骤的锂试剂缓慢逐滴滴加至反应瓶中,随后转入0℃搅拌10分钟,再转入-78℃反应1小时,得到黄色铜盐溶液。Take a 250mL two-necked round-bottom flask and dry it. Replace the argon three times, weigh cuprous cyanide (5.33g, 58.88mmol, 1.5equiv) and add it to the two-necked flask, replace the argon three times again, take 15mL of redistilled tetrahydrofuran and add it to the two-necked flask, at -78°C, extract the lithium reagent from the previous step and slowly add it dropwise to the reaction flask, then transfer it to 0°C and stir for 10 minutes, and then transfer it to -78°C to react for 1 hour to obtain a yellow copper salt solution.
取25mL单口圆底烧瓶备用,严格干燥置换氩气三次,依次抽取10mL重蒸后的四氢呋喃、2-环己烯-1-酮(3.78g,39.26mmol,1.0equiv)、三氟化硼乙醚溶液(4.95mL,39.26mmol,1.0equiv)加入单口瓶后将三者混匀。在-78℃下,抽取该溶液缓慢逐滴滴加至上一步骤的反应瓶中,于-78℃下反应4小时,反应结束后,用饱和氯化铵溶液淬灭(10mL),乙酸乙酯萃取(70mL×3);再依次用蒸馏水(50mL)和饱和食盐水(50mL)洗涤,最后加入适量无水硫酸钠干燥,减压浓缩除去溶剂后,利用柱层析进行分离纯化,洗脱剂体积比为(石油醚:乙酸乙酯=30:1→15:1),得到白色固体化合物Ⅳ(8.40g,80.7%)。Rf=0.5(石油醚:乙酸乙酯=4:1);通过TLC薄层色谱以及核磁数据表征其结构。具体如下:1H NMR(400MHz,CDCl3):δ=6.52(s,1H),3.79(s,3H),3.64(s,3H),3.53(tt,J=12.4,4.0Hz,1H),3.23(t,J=13.2Hz,1H),2.44-2.39(m,2H),2.39–2.30(m,2H),2.24(s,3H),2.13(s,3H),2.08(dd,J=5.6,3.6Hz,1H),1.77(dd,J=10.0,4.4Hz,2H)ppm;13C NMR(100MHz,CDCl3):δ=212.2,156.6,156.6,136.7,122.2,121.8,109.1,61.2,55.2,45.8,41.3,36.0,29.3,25.8,20.3,12.0ppm。Take a 25mL single-mouth round-bottom flask for use, strictly dry and replace argon three times, extract 10mL of redistilled tetrahydrofuran, 2-cyclohexene-1-one (3.78g, 39.26mmol, 1.0equiv), and boron trifluoride ether solution (4.95mL, 39.26mmol, 1.0equiv) in turn, add them to the single-mouth flask and mix them. At -78°C, extract the solution and slowly drop it into the reaction bottle of the previous step, react at -78°C for 4 hours, after the reaction is completed, quench with saturated ammonium chloride solution (10mL), extract with ethyl acetate (70mL×3); then wash with distilled water (50mL) and saturated brine (50mL) in turn, finally add an appropriate amount of anhydrous sodium sulfate to dry, concentrate under reduced pressure to remove the solvent, and separate and purify by column chromatography, the eluent volume ratio is (petroleum ether: ethyl acetate = 30:1→15:1), and obtain white solid compound IV (8.40g, 80.7%). R f = 0.5 (petroleum ether: ethyl acetate = 4: 1); its structure was characterized by TLC thin layer chromatography and nuclear magnetic resonance data. Specifically as follows: 1 H NMR (400MHz, CDCl 3 ): δ = 6.52 (s, 1H), 3.79 (s, 3H), 3.64 (s, 3H), 3.53 (tt, J = 12.4, 4.0 Hz, 1H), 3.23 (t, J = 13.2 Hz, 1H), 2.44-2.39 (m, 2H), 2.39–2.30 (m, 2H), 2.24 (s, 3H), 2.13 (s, 3H), 2.08 (dd, J = 5.6, 3.6 Hz, 1H), 1.77 (dd, J = 10.0, 4.4 Hz, 2H) ppm; 13 C NMR (100MHz, CDCl 3 ): δ=212.2,156.6,156.6,136.7,122.2,121.8,109.1,61.2,55.2,45.8,41.3,36.0,29.3,25.8,20.3,12.0ppm.
步骤5:Step 5:
取100mL双口圆底烧瓶备用,连接回流装置,干燥置换氩气后,称取化合物Ⅳ(1.12g,4.27mmol,1.0equiv)添加至双口瓶中再次置换氩气三次。在室温下,加入超干的N,N-二甲基甲酰胺(35-mL),溶解底物后,在搅拌下称取乙硫醇钠(1.13g,13.67mmol,3.2equiv)加入反应瓶中,升温至为153℃回流6小时,反应结束后,待体系冷却,加入15mL的2M HCl淬灭反应,二氯甲烷萃取(15mL);用蒸馏水(20mL)除去N,N-二甲基甲酰胺,依次用饱和碳酸氢钠溶液(15mL)和饱和食盐水(15mL)洗涤,最后加入适量无水硫酸钠干燥,减压浓缩除去溶剂后,利用柱层析进行分离纯化,洗脱剂体积比为(石油醚:乙酸乙酯=15:1),得到白色固体化合物Ⅴ(0.60g,56%),Rf=0.5(石油醚:乙酸乙酯=4:1)。通过TLC薄层色谱以及核磁数据表征其结构。具体如下:1H NMR(400MHz,CDCl3):δ=6.24(s,1H),3.76(s,3H),3.49(t,J=3.2Hz,1H),2.98(s,1H),2.23(s,3H),2.06(s,3H),2.05-2.00(m,1H),1.98(dd,J=12.4,2.8Hz,1H),1.83-1.68(m,3H),1.52(tt,J=12.4,3.6Hz,2H),1.41-1.30(m,1H)ppm;13C NMR(100MHz,CDCl3):δ=154.0,153.6,135.4,114.9,110.8,103.5,98.3,55.4,39.1,36.3,29.7,28.6,20.3,19.4,11.2ppm。Take a 100 mL two-necked round-bottom flask for standby use, connect it to a reflux device, dry and replace the argon, weigh compound IV (1.12 g, 4.27 mmol, 1.0 equiv), add it to the two-necked flask, and replace the argon again three times. At room temperature, ultra-dry N,N-dimethylformamide (35-mL) was added to dissolve the substrate, and sodium ethanethiolate (1.13 g, 13.67 mmol, 3.2 equiv) was weighed and added to the reaction bottle under stirring, and the temperature was raised to 153°C and refluxed for 6 hours. After the reaction was completed, the system was cooled, and 15 mL of 2M HCl was added to quench the reaction, and dichloromethane was extracted (15 mL); N,N-dimethylformamide was removed with distilled water (20 mL), and washed with saturated sodium bicarbonate solution (15 mL) and saturated brine (15 mL) in sequence, and finally added with an appropriate amount of anhydrous sodium sulfate to dry, concentrated under reduced pressure to remove the solvent, and separated and purified by column chromatography, the eluent volume ratio was (petroleum ether: ethyl acetate = 15:1), and white solid compound V (0.60 g, 56%) was obtained, R f = 0.5 (petroleum ether: ethyl acetate = 4:1). Its structure was characterized by TLC thin layer chromatography and nuclear magnetic resonance data. The details are as follows: 1H NMR (400MHz, CDCl 3 ): δ = 6.24 (s, 1H), 3.76 (s, 3H), 3.49 (t, J = 3.2Hz, 1H), 2.98 (s, 1H), 2.23 (s, 3H), 2.06 (s, 3H), 2.05-2.00 (m, 1H), 1.98 (dd, J = 1 2.4, 2.8Hz, 1H), 1.83-1.68 (m, 3H), 1.52 (tt, J=12.4, 3.6Hz, 2H), 1.41-1.30 (m, 1H)ppm; 13 C NMR (100MHz, CDCl 3 ): δ=154.0,153.6,135.4,114.9,110.8,103.5,98.3,55.4,39.1,36.3,29.7,28.6,20.3,19.4,11.2ppm.
步骤6:Step 6:
取100mL双口圆底烧瓶,干燥并置换三次氩气。在室温下,抽取15mL重蒸后的四氢呋喃,溶解化合物Ⅴ(500mg,2.02mmol,1.0equiv)并转移至双口瓶中。然后在-78℃下缓慢滴加入溶于超干四氢呋喃(20mL)的苯基三甲基三溴化铵(2.4g,6.25mmol,3.1equiv),-78℃下反应3小时后,移至室温反应12小时,反应结束后,砂芯漏斗抽滤,滤液经减压浓缩除去溶剂后,得到黄色固体备用。Take a 100mL two-necked round-bottom flask, dry it and replace the argon three times. At room temperature, extract 15mL of redistilled tetrahydrofuran, dissolve compound V (500mg, 2.02mmol, 1.0equiv) and transfer it to a two-necked flask. Then slowly drop phenyltrimethylammonium tribromide (2.4g, 6.25mmol, 3.1equiv) dissolved in ultra-dry tetrahydrofuran (20mL) at -78°C, react for 3 hours at -78°C, move to room temperature and react for 12 hours. After the reaction is completed, filter with a sand core funnel, and concentrate the filtrate under reduced pressure to remove the solvent to obtain a yellow solid for use.
取100mL双口圆底烧瓶备用,在室温下,抽取5mL二氯甲烷,溶解溴代反应所得的黄色固体化合物并转移至双口瓶中。0℃下以每秒2滴的速率加入0.5M的NaOH溶液(0.8g NaOH固体溶于40mL蒸馏水),滴加完毕后转移至室温下反应0.5小时。反应结束后,二氯甲烷萃取(10mL×3);再依次用蒸馏水(10mL)和饱和食盐水(10mL)洗涤,最后加入适量无水硫酸钠干燥,减压浓缩除去溶剂后,利用柱层析进行分离纯化,洗脱剂体积比为(石油醚:乙酸乙酯=20:1→15:1),得到黄色固体化合物Ⅵ(0.80g,35.7%),Rf=0.5(石油醚:乙酸乙酯=4:1)。通过TLC薄层色谱以及核磁数据表征其结构。具体如下:1H NMR(400MHz,CDCl3):δ=4.45(d,J=8.0Hz,1H),3.77(s,3H),3.74-3.71(m,1H),2.94-2.86(m,1H),2.76(dd,J=18.8,6.0Hz,1H),2.53-2.47(m,1H),2.37(s,3H),2.26(d,J=2.4Hz,1H),2.14(s,3H),2.11-2.04(m,1H),1.97-1.88(m,1H)ppm;13C NMR(100MHz,CDCl3):δ=207.6,151.7,151.3,136.8,124.1,123.1,112.5,80.4,61.5,45.8,29.3,27.3,26.6,20.0,13.3ppm。Take a 100mL double-mouthed round-bottomed flask for standby use. At room temperature, extract 5mL of dichloromethane, dissolve the yellow solid compound obtained by the bromination reaction and transfer it to a double-mouthed flask. Add 0.5M NaOH solution (0.8g NaOH solid dissolved in 40mL distilled water) at a rate of 2 drops per second at 0°C. After the addition is complete, transfer to room temperature for reaction for 0.5 hours. After the reaction is completed, extract with dichloromethane (10mL×3); then wash with distilled water (10mL) and saturated brine (10mL) in turn, and finally add an appropriate amount of anhydrous sodium sulfate to dry, concentrate under reduced pressure to remove the solvent, and separate and purify by column chromatography. The eluent volume ratio is (petroleum ether: ethyl acetate = 20:1→15:1), and a yellow solid compound VI (0.80g, 35.7%) is obtained, R f = 0.5 (petroleum ether: ethyl acetate = 4:1). Its structure is characterized by TLC thin-layer chromatography and nuclear magnetic resonance data. The details are as follows: 1 H NMR (400MHz, CDCl 3 ): δ = 4.45 (d, J = 8.0Hz, 1H), 3.77 (s, 3H), 3.74-3.71 (m, 1H), 2.94-2.86 (m, 1H), 2.76 (dd, J = 18.8, 6.0Hz, 1H), 2.53-2.47 (m, 1H) ), 2.37 (s, 3H), 2.26 (d, J = 2.4Hz, 1H), 2.14 (s, 3H), 2.11-2.04 (m, 1H), 1.97-1.88 (m, 1H)ppm; 13 C NMR (100MHz, CDCl 3 ): δ=207.6,151.7,151.3,136.8,124.1,123.1,112.5,80.4,61.5,45.8,29.3,27.3,26.6,20.0,13.3ppm.
综上所述,本发明公开了一种氧杂苯并[3.2.2]桥环化合物骨架的合成方法,以氧杂苯并[3.2.2]桥环骨架为目标,通过化学合成的方法,设计了一系列以常见的化学反应,首次构建氧杂苯并[3.2.2]桥环骨架。该方法操作简单、原料廉价、步骤简短,为后续其他类型含有或涉及氧杂苯并[3.2.2]桥环骨架的化合物的合成奠定了基础,体现该方法的优越性,具有较高的的实用价值。In summary, the present invention discloses a method for synthesizing an oxybenzo[3.2.2] bridged ring compound skeleton, which targets the oxybenzo[3.2.2] bridged ring skeleton, designs a series of common chemical reactions through chemical synthesis methods, and constructs the oxybenzo[3.2.2] bridged ring skeleton for the first time. The method is simple to operate, has cheap raw materials, and short steps, and lays a foundation for the subsequent synthesis of other types of compounds containing or involving the oxybenzo[3.2.2] bridged ring skeleton, embodies the superiority of the method, and has high practical value.
最后,还需要说明的是,术语“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者设备不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种过程、方法、物品或者设备所固有的要素。Finally, it should be noted that the terms "comprises," "includes," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements that are inherent to such process, method, article, or apparatus.
尽管已描述了本发明的优选实施例,但本领域内的技术人员一旦得知了基本创造性概念,则可对这些实施例作出另外的变更和修改。所以,所附权利要求意欲解释为包括优选实施例以及落入本发明范围的所有变更和修改。Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
显然,本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样,倘若本发明的这些修改和变型属于本发明权利要求及其等同技术的范围之内,则本发明也意图包含这些改动和变型在内。Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410927619.0A CN118638091A (en) | 2024-07-11 | 2024-07-11 | A method for synthesizing an oxabenzo[3.2.2]bridged ring compound skeleton |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410927619.0A CN118638091A (en) | 2024-07-11 | 2024-07-11 | A method for synthesizing an oxabenzo[3.2.2]bridged ring compound skeleton |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118638091A true CN118638091A (en) | 2024-09-13 |
Family
ID=92661345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410927619.0A Pending CN118638091A (en) | 2024-07-11 | 2024-07-11 | A method for synthesizing an oxabenzo[3.2.2]bridged ring compound skeleton |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118638091A (en) |
-
2024
- 2024-07-11 CN CN202410927619.0A patent/CN118638091A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109776559B (en) | Method for preparing dehydrated icaritin through total synthesis | |
CN103030647A (en) | Method for synthesizing glabridin | |
CN112679420B (en) | Preparation method of 2,5-dibromopyridine | |
CN113637022B (en) | A kind of method of synthesizing glabridin | |
CN112979497A (en) | Method for preparing 2-iodoaryl ether based on o-haloiodobenzene without catalyst | |
CN106749358B (en) | A method of synthesis 5- methoxyl group -4- hydroxyl -2- aldehyde radical phenyl boric acid pinacol ester | |
CN114560901A (en) | Preparation method of ergosterol or derivative thereof | |
CN101519393A (en) | Novel method for preparing Scopoletin | |
CN118638091A (en) | A method for synthesizing an oxabenzo[3.2.2]bridged ring compound skeleton | |
CN113149973A (en) | Synthesis method of engagliflozin | |
CN109535120B (en) | Preparation method of 7-substituted-3, 4,4, 7-tetrahydrocyclobutane coumarin-5-ketone | |
CN110683941B (en) | Bisoprolol fumarate related impurity and preparation method and application thereof | |
CN102766088A (en) | Novel process for synchronizing 4,4'-dibromo-2,2'-bipyridyl | |
CN113979891B (en) | Preparation method of clenbuterol and intermediate product thereof | |
CN116924889A (en) | Preparation method of cannabidiol intermediate | |
AU630013B2 (en) | Improved method of preparing an intermediate for the manufacture of bambuterol | |
CN103804187B (en) | Synthesis method of diethylstilbestrol compound pigeon pea ketonic acid A | |
CN113264850A (en) | Synthetic method of nootropic ketonic A | |
CN115181082B (en) | Synthetic method of natural molecule Moracin M | |
CN111116493A (en) | A kind of method for preparing Apabetalone, intermediate and preparation method thereof | |
CN110452097B (en) | Preparation method of 1-hydroxypyrene | |
CN110143909B (en) | Preparation method of bilirubin intermediate | |
CN114957284B (en) | Efficient synthesis method and application of natural product Lycibarbitine | |
CN112851619B (en) | A kind of synthetic method of isochroman compound containing selenium | |
Sierakowski | A convenient synthesis of two dibenzofurans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |